Overexpression of c-Met in cervical intraepithelial neoplasia

Purpose of investigation: The purpose of this study is to evaluate the significance of the c-Met / Hepatocyte Growth Factor Receptor (HGFR) expression in cervical intraepithelial neoplasia (CIN). Materials and Methods: Twenty-one patients from two types of cervical intraepithelial neoplasias (LSIL and HSIL), diagnosed in our clinic were studied with c-Met immunohistochemistry. Of the 21 cases, five were diagnosed as LSIL and 16 as Normal cervical mucosas from five patients were studied with c-Met as control cases. Results: Overexpression of c-Met was found in all five of LSIL specimens. C-Met overexpression was observed in 11 cases of HSIL. No c-Met overexpression was seen in any of the five control cases. Conclusion: These results revealed that c-Met oncogene overexpression is an important parameter in cervical early oncogenesis and may have a role in malignant transformation of cervical epithelial cells.

c-Met / HGFR overexpression; Cervical intraepithelial neoplasia; Immunohistochemistry

[1] Nakamura T., Teramoto H., Ichihara A.: “Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures”. Proc. Natl. Acad. Sci USA, 1986, 83, 6489.

[2] Weidner K.M., Arakaki N., Hartmann G., Vandekerckhove J., Weingart S., Rieder H. et al.: “Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. USA, 1991, 88, 7001.

[3] Montesano R., Matsumoto K., Nakamura T., Orci L.: “Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor”. Cell, 1991, 67, 901.

[4] Tsarfaty I., Resau J.H., Rulong S., Keydar I., Faletto D.L., Vande Woude G.F.: “The met proto-oncogene receptor and lumen formation”. Science, 1992, 257, 1258.

[5] Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F. et al.: “Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product”. Science, 1991, 251, 802.

[6] Naldini L., Vigna E., Narsimhan R.P., Gaudino G., Zarnegar R., Michalopoulos G.K. et al.: “Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-Met”. Oncogene, 1991, 6, 501.

[7] Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio P.M.: “Tyrosine kinase receptor indistinguishable from the c-met protein”. Nature, 1989, 339, 155.

[8] Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., Vande Woude G.: “Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors”. Proc. Natl. Acad. Sci USA, 1987, 84, 6379.

[9] Tempest P.R., Stratton M.R., Cooper C.S.: “Structure of the met protein and variation of met protein kinase activity among human tumour cell lines”. Br. J. Cancer, 1988, 58, 3.

[10] Beviglia L., Matsumoto K., Lin C.S., Ziober B.L., Kramer R.H.: “Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression”. Int. J. Cancer, 1997, 74, 301.

[11] Di Renzo M.F., Olivero M., Ferro S., Prat M., Bongarzone I., Pilotti S. et al.: “Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas”. Oncogene, 1992, 7, 2549.

[12] Di Renzo M.F., Poulsom R., Olivero M., Comoglio P.M., Lemoine N.R.: “Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer”. Cancer Res., 1995, 55, 1129.

[13] Ebert M., Yokoyama M., Friess H., Buchler M.W., Korc M.: “Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer”. Cancer Res., 1994, 54, 5775.

[14] Humphrey P.A., Zhu X., Zarnegar R., Swanson P.E., Ratliff T.L., Vollmer R.T. et al.: “Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma”. Am. J. Pathol., 1995, 147, 386.

[15] Joseph A., Weiss G.H., Jin L., Fuchs A., Chowdhury S., O’Shaugnessy P. et al.: “Expression of scatter factor in human bladder carcinoma”. J. Natl. Cancer Inst., 1995, 87, 372.

[16] Natali P.G., Prat M., Nicotra M.R., Bigotti A., Olivero M., Comoglio P.M. et al.: “Overexpression of the met/HGF receptor in renal cell carcinomas”. Int. J. Cancer, 1996, 69, 212.

[17] Pisters L.L., Troncoso P., Zhau H.E., Li W., von Eschenbach A.C., Chung L.W.: “c-met proto-oncogene expression in benign and malignant human prostate tissues”. J. Urol., 1995, 154, 293.

[18] Prat M., Narsimhan R.P., Crepaldi T., Nicotra M.R., Natali P.G., Comoglio P.M.: “The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors”. Int. J. Cancer, 1991, 49, 323.

[19] Tamatani T., Hattori K., Iyer A., Tamatani K., Oyasu R.: “Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro”. Carcinogenesis, 1999, 20, 957.

[20] Ueki T., Fujimoto J., Suzuki T., Yamamoto H., Okamoto E.: “Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma”. Hepatology, 1997, 25, 619.

[21] Umeki K., Shiota G., Kawasaki H.: “Clinical significance of c-met oncogene alterations in human colorectal cancer”. Oncology, 1999, 56, 314.

[22] Welch W.C., Kornblith P.L., Michalopoulos G.K., Petersen B.E., Beedle A., Gollin S.M. et al.: “Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells”. Anticancer Res 1999, 19, 1635.

[23] Pirog E.C., Kleter B., Olgac S., Bobkiewicz P., Lindeman J., Quint W.G. et al.: “Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma”. Am. J. Pathol., 2000, 157, 1055.

[24] zur Hausen H.: “Viruses in human cancers”. Science, 1991, 254, 1167.

[25] Gissman L.: “Detection of HPV DNA in human genital lesions”. J. Cell. Biochem., 1985, 96, 67.

[26] Arends M.J., Wyllie A.H., Bird C.C.: “Papillomaviruses and human cancer”. Hum. Pathol., 1990, 21, 686.

[27] Kermorgant S., Walker F., Hormi K., Dessirier V., Lewin M.J., Lehy T.: “Developmental expression and functionality of hepatocyte growth factor and c-Met in human fetal digestive tissues”. Gastroenterology, 1997, 112, 1635.

[28] Tsao M.S., Yang Y., Marcus A., Liu N., Mou L.: “Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer”. Hum.. Pathol., 2001, 32, 57.

[29] Wang Y., Selden C., Farnaud S., Calnan D., Hodgson H.J.: “Hepatocyte growth factor (HGF/SF) is expressed in human epithelial cells during embryonic development; studies by in situ hybridisation and northern blot analysis”. J. Anat., 1994, 185 (Pt 3), 543.

[30] Wolf H.K., Zarnegar R., Michalopoulos G.K.: “Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study”. Hepatology, 1991, 14, 488.

[31] Ayhan A., Baykal C., Al A.: “Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma”. Gynecol. Oncol., 2001, 83, 569.

[32] Baykal C., Ayhan A., Al A., Yuce K.: “Overexpression of the c- Met/HGF receptor and its prognostic significance in uterine cervix carcinomas”. Gynecol. Oncol., 2003, 88, 123.

[33] Ertoy D., Ayhan A., Sarac E., Karaagaoglu E., Yasui W., Tahara E.: “Clinicopathological implication of cripto expression in early stage invasive cervical carcinomas”. Eur. J. Cancer 2000, 36, 1002.

[34] Mathur S.P., Mathur R.S., Rust P.F., Young R.C.: “Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN)”. Am. J. Reprod. Immunol., 2001, 46, 280.

[35] Ngan H.Y., Cheung A.N., Liu S.S., Liu K.L., Tsao S.W.: “Telomerase assay and HPV 16/18 typing as adjunct to conventional cytological cervical cancer screening”. Tumour Biol., 2002, 23, 87.

[36] Berger A.J., Baege A., Guillemette T., Deeds J., Meyer R., Disbrow G. et al.: “Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins”. Am. J. Pathol., 2002, 161, 603.

[37] Chang J.L., Tsao Y.P., Liu D.W., Han C.P., Lee W.H., Chen S.L.: “The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix”. Gynecol. Oncol., 1999, 73, 62.

[38] Cheng W.F., Chen C.A., Lee C.N., Chen T.M., Hsieh F.J., Hsieh C.Y.: “Vascular endothelial growth factor in cervical carcinoma”. Obstet. Gynecol., 1999, 93, 761.

[39] Hashimoto I., Kodama J., Seki N., Hongo A., Yoshinouchi M., Okuda H. et al.: “Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer”. Br. J. Cancer, 2001, 85, 93.

[40] Kim J.W., Kim Y.T., Kim D.K., Song C.H., Lee J.W.: “Expression of epidermal growth factor receptor in carcinoma of the cervix”. Gynecol. Oncol., 1996, 60, 283.

[41] Leung T.W., Cheung A.N., Cheng D.K., Wong L.C., Ngan H.Y.: “Expressions of c-erbB-2, epidermal growth factor receptor and pan-ras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis”. Oncol. Rep., 2001, 8, 1159.

[42] Oh M.J., Choi J.H., Kim I.H., Lee Y.H., Huh J.Y., Park Y.K. et al.: “Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma”. Clin. Cancer Res., 2000, 6, 4760.

[43] Steller M.A., Delgado C.H., Bartels C.J., Woodworth C.D., Zou Z.: “Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells”. Cancer, Res., 1996, 56, 1761.

[44] Ueda M., Terai Y., Yamashita Y., Kumagai K., Ueki K., Yamaguchi H. et al.: “Correlation between vascular endothelial growth factor- C expression and invasion phenotype in cervical carcinomas”. Int. J. Cancer, 2002, 98, 335.

[45] Bachtiary B., Selzer E., Knocke T.H., Potter R., Obermair A.: “Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival”. Cancer Lett., 2002, 179, 197.

[46] Kim J.W., Kim Y.T., Kim D.K.: “Correlation between EGFR and c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in cervical carcinoma”. Yonsei Med. J., 1999, 40, 207.

[47] Miller A.C., Luo L., Chin W.K., Director-Myska A.E., Prasanna P.G., Blakely W.F.: “Proto-oncogene expression: a predictive assay for radiation biodosimetry applications”. Radiat. Prot. Dosimetry, 2002, 99, 295.

[48] Giordano S., Zhen Z., Medico E., Gaudino G., Galimi F., Comoglio P.M.: “Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene”. Proc. Natl. Acad. Sci. USA, 1993, 90, 649.

[49] Shimabukuro K., Ichinose S., Koike R., Kubota T., Yamaguchi M., Miyasaka M. et al.: “Hepatocyte growth factor/scatter factor is implicated in the mode of stromal invasion of uterine squamous cervical cancer”. Gynecol. Oncol., 2001, 83, 205.

[50] Rong S., Bodescot M., Blair D., Dunn J., Nakamura T., Mizuno K. et al.: “Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor”. Mol. Cell. Biol., 1992, 12, 5152.

[51] Wagatsuma S., Konno R., Sato S., Yajima A.: “Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma”. Cancer, 1998, 82, 520.

[52] Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S.: “Human papillomavirus and cervical cancer”. Lancet, 2007, 370, 890.

[53] ASCUS-LSIL Traige Study (ALTS) Group: “Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance”. Am. J. Obstet. Gynecol., 2003, 188, 1383.